Associations between <i>Mycobacterium tuberculosis</i> Beijing genotype and drug resistance to four first-line drugs: a survey in China

doi:10.1007/s11684-017-0610-z

Front. Med.

2018, Vol. 12

Issue (1) : 92-97 https://doi.org/10.1007/s11684-017-0610-z

RESEARCH ARTICLE

Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China

Haican Liu¹, Yuanyuan Zhang¹, Zhiguang Liu¹, Jinghua Liu^1,², Yolande Hauck^1,², Jiao Liu^1,⁴, Haiyan Dong¹, Jie Liu¹, Xiuqin Zhao¹, Bing Lu¹, Yi Jiang¹, Gilles Vergnaud^2,⁵, Christine Pourcel²(

), Kanglin Wan^1,^2,³(

)

¹. State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
². University Paris-Sud, Institut de Génétique et Microbiologie, UMR 8621, Orsay, France
³. CNRS, Orsay, France
⁴. Department of Epidemiology and Health Statistics, Public Health of Central South University, Changsha 421001, China
⁵. DGA/MRIS-Mission pour la Recherche et l’Innovation Scientifique, Bagneux, France

Download: PDF(106 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Investigations on the genetic diversity of Mycobacterium tuberculosis in China have shown that Beijing genotype strains play a dominant role. To study the association between the M.?tuberculosis Beijing genotype and the drug-resistance phenotype, 1286 M. tuberculosis clinical isolates together with epidemiological and clinical information of patients were collected from the center for tuberculosis (TB) prevention and control or TB hospitals in Beijing municipality and nine provinces or autonomous regions in China. Drug resistance testing was conducted on all the isolates to the four first-line anti-TB drugs (isoniazid, rifampicin, streptomycin, and ethambutol). A total of 585 strains were found to be resistant to at least one of the four anti-TB drugs. The Beijing family strains consisted of 499 (53.20%) drug-sensitive strains and 439 (46.80%) drug-resistant strains, whereas the non-Beijing family strains comprised 202 (58.05%) drug-sensitive strains and 146 (41.95%) drug-resistant strains. No significant difference was observed in prevalence (c²=2.41, P>0.05) between the drug-resistant and drug-sensitive strains among the Beijing family strains. Analysis of monoresistance, multidrug-resistant TB, and geographic distribution of drug resistance did not find any relationships between the M.?tuberculosis Beijing genotype and drug-resistance phenotype in China. Results confirmed that the Beijing genotype, the predominant M. tuberculosis genotype in China, was not associated with drug resistance.

Keywords tuberculosis drug resistance genotype molecular biology

Corresponding Author(s): Christine Pourcel,Kanglin Wan

Just Accepted Date: 30 November 2017 Online First Date: 05 January 2018 Issue Date: 06 February 2018

Cite this article:

Haican Liu,Yuanyuan Zhang,Zhiguang Liu, et al. Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China[J]. Front. Med., 2018, 12(1): 92-97.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-017-0610-z
https://academic.hep.com.cn/fmd/EN/Y2018/V12/I1/92

Tab.1 Relationship between the Beijing genotype and drug resistance in 10 provinces of China

Tab.2 Comparison of the relationship between the Beijing genotype and single-drug resistance to four drugs

Province	Drug susceptibility test	Total (%)	Beijing (%)	Non-Beijing (%)	c²	P	OR (95% CI)
Total of 10 provinces	Drug susceptibility	701 (54.51)	499 (53.19)	202 (58.04)
	Mono-drug resistance	153 (11.90)	119 (12.68)	34 (9.77)	2.730	0.098	0.706 (0.466–1.069)
	Multidrug resistance	432 (33.59)	320 (34.11)	112 (32.18)	1.114	0.291	0.865 (0.660–1.133)
Beijing	Drug susceptibility	81 (77.88)	76 (77.55)	5 (83.33)
	Mono-drug resistance	11 (10.58)	10 (10.20)	1 (16.66)	–	0.545*	1.520 (0.161–14.364)
	Multidrug resistance	12 (11.54)	12 (12.24)	0 (0.00)	–	1.000*	0.938 (0.887–0.992)
Tibet	Drug susceptibility	73 (33.80)	68 (34.87)	5 (23.80)
	Mono-drug resistance	24 (11.11)	22 (11.28)	2 (9.52)	0.000	1.000	1.236 (0.224–6.828)
	Multidrug resistance	119 (50.09)	105 (53.84)	14 (66.66)	1.226	0.268	1.813 (0.625–2.264)
Jilin	Drug susceptibility	5 (16.67)	5 (19.23)	0 (0.00)
	Mono-drug resistance	3 (10.00)	3 (11.53)	0 (0.00)	–	–	–
	Multidrug resistance	22 (73.33)	18 (69.23)	4 (100.00)	–	0.561*	1.222 (1.004–1.488)
Gansu	Drug susceptibility	72 (45.57)	61 (45.52)	11 (45.83)
	Mono-drug resistance	46 (29.11)	39 (29.10)	7 (29.16)	0.000	0.993	0.995 (0.356–2.786)
	Multidrug resistance	40 (25.32)	34 (25.37)	6 (25.00)	0.002	0.969	0.979 (0.332–2.880)
Henan	Drug susceptibility	43 (59.72)	36 (59.01)	7 (63.63)
	Mono-drug resistance	9 (12.50)	7 (11.47)	2 (18.18)	0.000	1.000	1.469 (0.251–8.607)
	Multidrug resistance	20 (27.78)	18 (29.50)	2 (18.18)	0.076	0.782	0.571 (0.108–3.036)
Hunan	Drug susceptibility	50 (61.73)	37 (66.07)	13 (52.00)
	Mono-drug resistance	7 (8.64)	4 (7.14)	3 (12.00)	0.231	0.631	2.135 (0.420–10.839)
	Multidrug resistance	24 (29.63)	15 (26.78)	9 (36.00)	1.027	0.311	1.708 (0.603–4.833)
Xinjiang	Drug susceptibility	121 (66.12)	79 (65.83)	42 (66.66)
	Mono-drug resistance	22 (12.02)	12 (10.00)	10 (15.87)	0.929	0.335	1.567 (0.625–3.929)
	Multidrug resistance	40 (21.86)	29 (24.16)	11 (17.46)	0.708	0.400	0.713 (0.324–1.570)
Sichuan	Drug susceptibility	12 (20.00)	6 (17.14)	6 (24.00)
	Mono-drug resistance	3 (5.00)	2 (5.71)	1 (4.00)	0.000	1.000	0.500 (0.035–7.104)
	Multidrug resistance	45 (75.00)	27 (77.14)	18 (72.00)	0.389	0.533	0.667 (0.186–2.396)
Fujian	Drug susceptibility	98 (55.37)	54 (54.00)	44 (57.14)
	Mono-drug resistance	1 (0.56)	1 (1.00)	0 (0.00)	–	1.000*	0.551 (0.461–0.659)
	Multidrug resistance	78 (44.07)	45 (45.00)	33 (42.85)	0.118	0.731	0.900 (0.494–1.640)
Guangxi	Drug susceptibility	145 (70.73)	76 (67.25)	69 (75.00)
	Mono-drug resistance	27 (13.17)	19 (16.81)	8 (8.69)	2.968	0.085	0.464 (0.191–1.127)
	Multidrug resistance	33 (16.10)	18 (15.92)	15 (16.30)	0.049	0.825	0.918 (0.430–1.960)
Total		1286	938	348

Tab.3 Comparison of the relationship between the Beijing genotype and drug resistance in 10 provinces of China

1	van Soolingen D, Qian L, de Haas PE, Douglas JT, Traore H, Portaels F, Qing HZ, Enkhsaikan D, Nymadawa P, van Embden JD. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995; 33(12): 3234–3238 pmid: 8586708
2	Mokrousov I, Ly HM, Otten T, Lan NN, Vyshnevskyi B, Hoffner S, Narvskaya O. Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography. Genome Res 2005; 15(10): 1357–1364 https://doi.org/10.1101/gr.3840605 pmid: 16169923
3	Qian L, Van Embden JD, Van Der Zanden AG, Weltevreden EF, Duanmu H, Douglas JT. Retrospective analysis of the Beijing family of Mycobacterium tuberculosis in preserved lung tissues. J Clin Microbiol 1999; 37(2): 471–474 pmid: 9889247
4	Li WM, Wang SM, Li CY, Liu YH, Shen GM, Zhang XX, Niu TG, Gao Q, van Soolingen D, Kremer K, Duanmu HJ. Molecular epidemiology of Mycobacterium tuberculosis in China: a nationwide random survey in 2000. Int J Tuberc Lung Dis 2005; 9(12): 1314–1319 pmid: 16466052
5	Wan K, Liu J, Hauck Y, Zhang Y, Liu J, Zhao X, Liu Z, Lu B, Dong H, Jiang Y, Kremer K, Vergnaud G, van Soolingen D, Pourcel C. Investigation on Mycobacterium tuberculosis diversity in China and the origin of the Beijing clade. PLoS One 2011; 6(12): e29190 https://doi.org/10.1371/journal.pone.0029190 pmid: 22220207
6	WHO. Global Tuberculosis Report, 2016. 1st ed. Geneva: World Health Organization, 2016
7	Cox HS, Kubica T, Doshetov D, Kebede Y, Rüsch-Gerdess S, Niemann S. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 2005; 6(1): 134 https://doi.org/10.1186/1465-9921-6-134 pmid: 16277659
8	Sun YJ, Lee AS, Wong SY, Heersma H, Kremer K, van Soolingen D, Paton NI. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int J Tuberc Lung Dis 2007; 11(4): 436–442 pmid: 17394691
9	Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002; 40(6): 1930–1937 https://doi.org/10.1128/JCM.40.6.1930-1937.2002 pmid: 12037045
10	Krüüner A, Hoffner SE, Sillastu H, Danilovits M, Levina K, Svenson SB, Ghebremichael S, Koivula T, Källenius G. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39(9): 3339–3345 https://doi.org/10.1128/JCM.39.9.3339-3345.2001 pmid: 11526173
11	Rieder HL, Chonde TM, Myking H, Urbanczik R, Laszlo A, Kim S, Van Deun A. The public health service national tuberculosis reference laboratory and the national laboratory network: minimum requirements, role and operation in a low-income country. International Union Against Tuberculosis And Lung Disease (IUATLD), 1998. 68
12	Driscoll JR, Bifani PJ, Mathema B, McGarry MA, Zickas GM, Kreiswirth BN, Taber HW. Spoligologos: a bioinformatic approach to displaying and analyzing Mycobacterium tuberculosis data. Emerg Infect Dis 2002; 8(11): 1306–1309 https://doi.org/10.3201/eid0811.020174 pmid: 12453361
13	Filliol I, Motiwala AS, Cavatore M, Qi W, Hazbón MH, Bobadilla del Valle M, Fyfe J, García-García L, Rastogi N, Sola C, Zozio T, Guerrero MI, León CI, Crabtree J, Angiuoli S, Eisenach KD, Durmaz R, Joloba ML, Rendón A, Sifuentes-Osornio J, Ponce de León A, Cave MD, Fleischmann R, Whittam TS, Alland D. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 2006; 188(2): 759–772 https://doi.org/10.1128/JB.188.2.759-772.2006 pmid: 16385065
14	Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002; 10(1): 45–52 https://doi.org/10.1016/S0966-842X(01)02277-6 pmid: 11755085
15	Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8(8): 843–849 https://doi.org/10.3201/eid0805.020002 pmid: 12141971
16	Filliol I, Driscoll JR, van Soolingen D, Kreiswirth BN, Kremer K, Valétudie G, Dang DA, Barlow R, Banerjee D, Bifani PJ, Brudey K, Cataldi A, Cooksey RC, Cousins DV, Dale JW, Dellagostin OA, Drobniewski F, Engelmann G, Ferdinand S, Gascoyne-Binzi D, Gordon M, Gutierrez MC, Haas WH, Heersma H, Kassa-Kelembho E, Ho ML, Makristathis A, Mammina C, Martin G, Moström P, Mokrousov I, Narbonne V, Narvskaya O, Nastasi A, Niobe-Eyangoh SN, Pape JW, Rasolofo-Razanamparany V, Ridell M, Rossetti ML, Stauffer F, Suffys PN, Takiff H, Texier-Maugein J, Vincent V, de Waard JH, Sola C, Rastogi N. Snapshot of moving and expanding clones of Mycobacterium tuberculosis and their global distribution assessed by spoligotyping in an international study. J Clin Microbiol 2003; 41(5): 1963–1970 https://doi.org/10.1128/JCM.41.5.1963-1970.2003 pmid: 12734235
17	Ebrahimi-Rad M, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, Kreiswirth B, Blazquez J, Jouan M, van Soolingen D, Gicquel B. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 2003; 9(7): 838–845 https://doi.org/10.3201/eid0907.020803 pmid: 12890325
18	Bifani PJ, Mathema B, Liu Z, Moghazeh SL, Shopsin B, Tempalski B, Driscol J, Frothingham R, Musser JM, Alcabes P, Kreiswirth BN. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA 1999; 282(24): 2321–2327 https://doi.org/10.1001/jama.282.24.2321 pmid: 10612319
19	Bifani P, Mathema B, Campo M, Moghazeh S, Nivin B, Shashkina E, Driscoll J, Munsiff SS, Frothingham R, Kreiswirth BN. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Infect Dis 2001; 7(5): 842–848 https://doi.org/10.3201/eid0705.010512 pmid: 11747697
20	Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 2000; 6(3): 302–305 https://doi.org/10.3201/eid0603.000312 pmid: 10827122
21	van Crevel R, Parwati I, Sahiratmadja E, Marzuki S, Ottenhoff TH, Netea MG, van der Ven A, Nelwan RH, van der Meer JW, Alisjahbana B, van de Vosse E. Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. J Infect Dis 2009; 200(11): 1671–1674 https://doi.org/10.1086/648477 pmid: 19863441
22	Laserson KF, Osorio L, Sheppard JD, Hernández H, Benitez AM, Brim S, Woodley CL, Hazbón MH, Villegas MV, Castaño MC, Henriquez N, Rodriguez E, Metchock B, Binkin NJ. Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998. Int J Tuberc Lung Dis 2000; 4(7): 673–683 pmid: 10907771
23	Chan MY, Borgdorff M, Yip CW, de Haas PE, Wong WS, Kam KM, Van Soolingen D. Seventy percent of the Mycobacterium tuberculosis isolates in Hong Kong represent the Beijing genotype. Epidemiol Infect 2001; 127(1): 169–171 https://doi.org/10.1017/S0950268801005659 pmid: 11561969

[1]	Shengfen Wang, Yang Zhou, Bing Zhao, Xichao Ou, Hui Xia, Yang Zheng, Yuanyuan Song, Qian Cheng, Xinyang Wang, Yanlin Zhao. Characteristics of compensatory mutations in the rpoC gene and their association with compensated transmission of Mycobacterium tuberculosis[J]. Front. Med., 2020, 14(1): 51-59.
[2]	Honglu Zhou, Songmei Wang, Lorenz von Seidlein, Xuanyi Wang. The epidemiology of norovirus gastroenteritis in China: disease burden and distribution of genotypes[J]. Front. Med., 2020, 14(1): 1-7.
[3]	Jing Yue, Bo Zhang, Mingyue Wang, Junning Yao, Yifan Zhou, Ding Ma, Lei Jin. Effect of antitubercular treatment on the pregnancy outcomes and prognoses of patients with genital tuberculosis[J]. Front. Med., 2019, 13(1): 121-125.
[4]	Liqin Wang, Rene Bernards. Taking advantage of drug resistance, a new approach in the war on cancer[J]. Front. Med., 2018, 12(4): 490-495.
[5]	Xinxin Xu, Yinshi Guo, Qiuying Li, Ling Yang, Jianqiang Kang. Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report[J]. Front. Med., 2018, 12(3): 330-333.
[6]	Chongguang Yang, Qian Gao. *Recent transmission of Mycobacterium tuberculosis* in China: the implication of molecular epidemiology for tuberculosis control**[J]. Front. Med., 2018, 12(1): 76-83.
[7]	Peter B. Alexander,Xiao-Fan Wang. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies[J]. Front. Med., 2015, 9(2): 134-138.
[8]	Hui Li,Ran Li,Jiuxin Qu,Xiaomin Yu,Zhixin Cao,Yingmei Liu,Bin Cao. Ventricular tachycardia in a disseminated MDR-TB patient: a case report and brief review of literature[J]. Front. Med., 2014, 8(2): 259-263.
[9]	Xu Chen, Xiaomao Xu, Fei Xiao. Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype[J]. Front Med, 2013, 7(4): 425-432.
[10]	Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line[J]. Front Med, 2013, 7(4): 462-476.
[11]	Xiangwei Li, Yu Yang, Jianmin Liu, Feng Zhou, Wei Cui, Ling Guan, Fei Shen, Cong Gao, Mufei Li, Qi Jin, Lei Gao. Treatment outcomes of pulmonary tuberculosis in the past decade in the mainland of China: a meta-analysis[J]. Front Med, 2013, 7(3): 354-366.
[12]	Fung Zhao, Eric W.-F. Lam. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance[J]. Front Med, 2012, 6(4): 376-380.
[13]	Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG, . Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma[J]. Front. Med., 2010, 4(4): 419-429.
[14]	Shi-Ming CHENG MD, Yu-Ji LAI MS, Er-Yong LIU MS, Lin ZHOU MD, Xue-Jing WANG MS, Qiu-Lan CHEN MS, Dong-Ming LI MS, Ning WANG MD, . Study on factors affecting TB/HIV co-infection in four counties of China[J]. Front. Med., 2010, 4(2): 185-191.
[15]	Rong WANG, Shangwei WU, Xue LI, Ping HE, Yunde LIU. Detection of AmpC β-lactamase and drug resistance of Enterobacter cloacae[J]. Front Med Chin, 2009, 3(1): 72-75.

Viewed

Full text

Abstract

Cited

Shared

Discussed